{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T03:02:20Z","timestamp":1791342140294,"version":"4.3.1"},"reference-count":25,"publisher":"Wiley","issue":"5","license":[{"start":{"date-parts":[[2010,1,11]],"date-time":"2010-01-11T00:00:00Z","timestamp":1263168000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer"],"published-print":{"date-parts":[[2010,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>BACKGROUND:<\/jats:title><jats:p>Intrahepatic arterial yttrium 90 (<jats:sup>90<\/jats:sup>Y) microspheres have been proposed as a less toxic, less invasive therapeutic option to transhepatic arterial chemoembolization (TACE) for patients with surgically unresectable hepatocellular carcinoma (HCC). TACE has demonstrated the ability to prolong survival. However, long\u2010term survival remains uncertain.<\/jats:p><\/jats:sec><jats:sec><jats:title>METHODS:<\/jats:title><jats:p>In a 2\u2010cohort experience in the treatment of North American patients who had advanced, unresectable, biopsy\u2010proven HCC, 691 patients received repetitive, cisplatin\u2010based chemoembolization; and a separate cohort of 99 patients who had similar treatment criteria received a planned, single dose of <jats:sup>90<\/jats:sup>Y. Over the study period, an additional 142 patients were followed without treatment (total, 932 patients).<\/jats:p><\/jats:sec><jats:sec><jats:title>RESULTS:<\/jats:title><jats:p>Overall survival was slightly better in the <jats:sup>90<\/jats:sup>Y group compared with the TACE group (median survival, 11.5 months vs 8.5 months). However, the selection criteria indicated a small but significant bias toward milder disease in the <jats:sup>90<\/jats:sup>Y group. By using stratification into a 3\u2010tier model with patients dichotomized according to bilirubin levels &lt;1.5 mg\/dL, the absence of portal vein thrombosis (PVT), and low \u03b1\u2010fetoprotein plasma levels (&lt;25 U\/dL), an analysis of survival in clinical subgroups indicated that the 2 treatments resulted in similar survival. In addition, patients who had PVT or high \u03b1\u2010fetoprotein levels also had similar survival in both treatment groups.<\/jats:p><\/jats:sec><jats:sec><jats:title>CONCLUSIONS:<\/jats:title><jats:p>Given the current evidence of therapeutic equivalence in survival, <jats:sup>90<\/jats:sup>Y and TACE appeared to be equivalent regional therapies for patients with unresectable, nonmetastatic HCC. Cancer 2010. \u00a9 2010 American Cancer Society.<\/jats:p><\/jats:sec>","DOI":"10.1002\/cncr.24884","type":"journal-article","created":{"date-parts":[[2010,1,11]],"date-time":"2010-01-11T16:36:45Z","timestamp":1263227805000},"page":"1305-1314","source":"Crossref","is-referenced-by-count":151,"title":["Therapeutic equivalence in survival for hepatic arterial chemoembolization and yttrium 90 microsphere treatments in unresectable hepatocellular carcinoma"],"prefix":"10.1002","volume":"116","author":[{"given":"Brian I.","family":"Carr","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Venkateswarlu","family":"Kondragunta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shama C.","family":"Buch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert A.","family":"Branch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2010,1,11]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00535-005-1566-3"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2003.50047"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)08649-X"},{"key":"e_1_2_6_5_2","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2002.33156"},{"key":"e_1_2_6_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/S1051-0443(07)61790-4"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2004.09.034"},{"key":"e_1_2_6_8_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.20036"},{"key":"e_1_2_6_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.21980"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-05-1730"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.14.518"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijrobp.2007.05.009"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.11111"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19891015)64:8<1586::AID-CNCR2820640805>3.0.CO;2-E"},{"key":"e_1_2_6_15_2","first-page":"79","article-title":"Hepatic artery chemoembolization for advanced stage HCC: experience of 650 patients","volume":"49","author":"Carr BI","year":"2002","journal-title":"Hepatogastroenterology."},{"key":"e_1_2_6_16_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00270-006-0062-3"},{"key":"e_1_2_6_17_2","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19920115)69:2<327::AID-CNCR2820690209>3.0.CO;2-U"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-007-9995-x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.RVI.0000233785.75257.9A"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1245\/s10434-007-9705-0"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.7861\/clinmedicine.7-4-351"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jvir.2007.08.027"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.2008.05487.x"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-007-9041-2"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1994.tb01256.x"},{"key":"e_1_2_6_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-007-9750-3"}],"container-title":["Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fcncr.24884","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/cncr.24884","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,12]],"date-time":"2025-10-12T19:13:45Z","timestamp":1760296425000},"score":1,"resource":{"primary":{"URL":"https:\/\/acsjournals.onlinelibrary.wiley.com\/doi\/10.1002\/cncr.24884"}},"subtitle":["A Two\u2010Cohort Study"],"short-title":[],"issued":{"date-parts":[[2010,1,11]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2010,3]]}},"alternative-id":["10.1002\/cncr.24884"],"URL":"https:\/\/doi.org\/10.1002\/cncr.24884","archive":["Portico"],"relation":{},"ISSN":["0008-543X","1097-0142"],"issn-type":[{"value":"0008-543X","type":"print"},{"value":"1097-0142","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,1,11]]}}}